Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-10-16
2010-10-19
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S292000
Reexamination Certificate
active
07816368
ABSTRACT:
The present disclosure relates to pyridoindolone derivatives of general formula (I):in which R1to R5are as defined in the specification, to processes for preparing said derivatives, and to methods of use thereof.
REFERENCES:
patent: 4263304 (1981-04-01), Ishizumi et al.
patent: 4835160 (1989-05-01), Bisagni et al.
patent: 5880126 (1999-03-01), Skuballa et al.
patent: 6503888 (2003-01-01), Kaplitt et al.
patent: 6967203 (2005-11-01), Bourrie et al.
patent: 7390818 (2008-06-01), Bourrie et al.
patent: 2002/0156016 (2002-10-01), Minuk
patent: 2004/0122036 (2004-06-01), Bourrie et al.
patent: 2007/0129365 (2007-06-01), Bourrie et al.
patent: 2008/0214538 (2008-09-01), Bourrie et al.
patent: 9708409 (1997-03-01), None
patent: 2 003 999 (1969-11-01), None
patent: 2 765 581 (1999-01-01), None
patent: 2 765 582 (1999-01-01), None
patent: 1 268 772 (1972-03-01), None
patent: 833971 (1981-05-01), None
patent: WO 99/51597 (1999-10-01), None
patent: WO 01/09129 (2001-02-01), None
patent: WO 02/087574 (2002-11-01), None
patent: WO 02/087575 (2002-11-01), None
patent: WO 2004/041817 (2004-05-01), None
patent: WO 2005/108398 (2005-11-01), None
patent: WO 2007/045758 (2007-04-01), None
Nicholson-Guthrie et al., Cancer Letters, (2001) pp. 27-30.
Goodman and Gilman Pharm. 9th Ed. Pharmacological Basis of Therapeutics (1996) pp. 1225-1232 and p. 1269-1271.
Cecil Text book of Medicine 20th Edition (1997) pp. 1002-1009.
Jaworska et al., Review of Methods for Assesing the Applicability domains of SARS and QSARS, ( Sep. 2004), 1-8.
U.S. Appl. No. 12/100,079, filed Apr. 9, 2008, Muneaux et al.
Estenne et al, Derwent Patent Abstract No. 199909 (2003), (Abstract of FR 2 765 582).
Furihata, C., et al., In Vivo Short-Term Assays For Tumor Initiation And Promotion In The Grandular Stomach Of Fischer Rats, Mutation Research, (1995), vol. 339, No. 1, pp. 15-35.
Furihata, C., et al., Unscheduled DNA Synthesis In Rat Stomach-Short-Term Assay Of Potential Stomach Carcinogens, Banbury Report, (1982), vol. 13, pp. 123-135.
Goldman M.D., et al., Cecil, Textbook of Medicine, 21st edition, vol. 1, published 2000 by W.B. Saunders Co. (PA), pp. 1060-1074.
Golovko, T., et al., A New Approach To The Synthesis Of Functionally-Substituted Pyrido 2, 3-D Indoles, Mendeleev Communications, (1995), vol. 6, pp. 226-227.
Goodman & Gilman, Section X. Chemotherapy of Neoplastic Diseases, Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th Ed., (1996) pp. 1225-1232 and pp. 1269-1271.
Kelland, of Mice and Men: Values and Liabilities of the Athymic Nude Mouse Model in Anticancer Drug Development, Abstract—Eur J Cancer. Apr. 2004; 40(6); pp. 823-836.
Molina, P., et al., Annulation Of Pyridine To Indole By A Tandem Aza-Wittig/Electrocyclization Strategy: Synthesis Of Pyrido 2, 3-B Indoles, Synthesis, (1989), vol. 11, pp. 878-880.
Nicholson-Guthrie et al, Urine GABA Levels in Ovarian Cancer Patients: elevated GABA in malignancy, Cancer Letters, vol. 162, Issue 1, (2001), pp. 27-30.
Peterson et al, Integrating Pharmacology and in vivo Cancer Models in Preclinical and Clinical Drug Development, Eur J Cancer, 40 (2004) pp. 837-844.
Sausville et al, Contributions of Human Tumor Xenografts to Anticancer Drug Development, Cancer Res. 2006; 66(7), Apr. 1, 2006; pp. 3351-3354.
Abstract No. 1982-25808e (XP-002184731, DW 198213) (1982).
Derwent Patent Abstract No. 196800 (2003).
Bourrie Bernard
Casellas Pierre
Derocq Jean-Marie
Jegham Samir
Muneaux Yvette
Bender Kelly L.
Gembeh Shirley V
Hartley Michael G
McCaslin R. Brian
sanofi-aventis
LandOfFree
Pyridoindolone derivatives substituted in the 3-position by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridoindolone derivatives substituted in the 3-position by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridoindolone derivatives substituted in the 3-position by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4187588